MANY ASSAYS REPORTED AS TYPE I INTERFERON PATHWAY ACTIVATION BIOMARKERS ARE MORE RESPONSIVE TO OTHER INTERFERON SUBTYPES OR INFLAMMATORY MEDIATORS